Phaseline

Targets › GYPC

GYPC (Glycophorin-C): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Mar 2027.

This protein is a minor sialoglycoprotein in human erythrocyte membranes. The blood group Gerbich antigens and receptors for Plasmodium falciparum merozoites are most likely located within the extracellular domain. (UniProt, P04921)

Open in Phaseline: the race on GYPC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beijing BiotechEB-DTNB-NK
Dual-target GD2/B7-H3 CAR-NK cells with IL-15 support and inducible safety switch
GYPC, CD276Phase 1Relapsed NeuroblastomaMar 2027
Sun Yat-Sen University Cancer CenterGD2/B7H3 CAR-T cell therapy
Dual-targeted CAR-T cells recognizing GD2 and B7H3 antigens
GYPC, B7H3Phase 1Neuroblastoma (NB)Dec 2027
Baylor College of MedicineiC9-GD2 T Cells
GD2-targeting chimeric antigen receptor (CAR) T cells with iCaspase-9 suicide safety switc
GYPCPhase 1NeuroblastomaOct 2030

Conditions

Neuroblastoma (1) Relapsed Neuroblastoma (1) Neuroblastoma (NB) (1)

Modalities

mixed (2), other (1)

Companies

Baylor College of Medicine (1) Beijing Biotech (1) Sun Yat-Sen University Cancer Center (1)

Related targets

CD276 (1) B7H3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.